Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause (IMAP): Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study.

Karen L. Diepstra,Liz Barr,David Palm,Evelyn Hogg,Katie R. Mollan,Laney Henley,Angela M. Stover,Jane M. Simoni,Jeremy Sugarman,Brandon Brown,John A. Sauceda,Steven G. Deeks,Lawrence Fox,Rajesh T. Gandhi,Doug Smith,Jonathan Z. Li,Karine Dubé

Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause (IMAP): Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study.

2021

Karen L. Diepstra
Liz Barr
David Palm
Evelyn Hogg
Katie R. Mollan
Laney Henley
Angela M. Stover
Jane M. Simoni
Jeremy Sugarman
Brandon Brown
John A. Sauceda
Steven G. Deeks
Lawrence Fox
Rajesh T. Gandhi
Doug Smith
Jonathan Z. Li
Karine Dubé

The AIDS Clinical Trials Group (ACTG) A5345 study included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antiretroviral treatment d...

Keywords:

Viral load
antiretroviral treatment
HIV/AIDS
Clinical trial
Financial compensation
Biomarker (medicine)
Family medicine
MEDLINE
Cohort
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations